LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that members of Inotek’s leadership team are scheduled to participate at the following investor conferences in November:
Global Mizuho Investor Conference in New York City
- Date: November 14th, 2016
- Attendee: Claudine Prowse, PhD, Vice President, Strategy and IRO
Stifel 2016 Healthcare Conference in New York City
- Presentation: November 16th, 2016 at 10:15 a.m. EST
- Attendees: David Southwell, President and Chief Executive Officer; Rudolf A. Baumgartner, MD, Executive Vice President, Chief Medical Officer; and Claudine Prowse, PhD, Vice President, Strategy and IRO
Piper Jaffray 28th Annual Healthcare Conference in New York City
- Presentation: November 29th, 2016 at 12:30 p.m. EST
- Attendees: David Southwell, President and Chief Executive Officer; Rudolf A. Baumgartner, MD, Executive Vice President, Chief Medical Officer; and Claudine Prowse, PhD, Vice President, Strategy and IRO
A live audio webcast of the Stifel presentation will be available on the Investors section of the company’s website, www.inotekpharma.com. A replay of the presentation will be archived on the Inotek website following the conference.
About Inotek Pharmaceuticals Corporation
Inotek
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek’s
laboratories and is designed to restore the eye’s natural pressure
control mechanism. Additionally, the Company is evaluating the potential
for selective adenosine mimetics to address optic neuropathies and other
degenerative retinal diseases. For more information, please visit www.inotekpharma.com.
The inclusion of our website address here and elsewhere in this press
release does not include or incorporate by reference the information on
our website into this press release.
Forward-Looking Statements
This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on these
statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may" or
similar expressions. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, the Company
cannot guarantee such outcomes. Accordingly, you should not place undue
reliance on these forward-looking statements. All such statements speak
only as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.